EDX Medical Group (LSE:EDX) has named Professor Michael Owen, co-founder of Sanofi-acquired Kymab and a former GlaxoSmithKline executive, as non-executive Chairman with immediate effect. He succeeds Jason Holt, who has chaired the board since the company was founded.
What was announced
EDX Medical Group (LSE:EDX) plc, the AIM-quoted digital diagnostics company, said on 30 October 2026 that Professor Michael John Owen has been appointed non-executive Chairman, effective immediately.
He replaces Jason Holt, who has led the board since the company's inception. Mr Holt is stepping down to focus on his other chairmanships and his charitable interests.
The company said the announcement contains inside information under the UK Market Abuse Regulation. It does not disclose Professor Owen's fee, the length of his appointment or whether the board regards him as independent.
Who is Michael Owen
Professor Owen, aged 75, is described by EDX as an experienced Research and Development executive and non-executive director with a record of global executive leadership. The company says he has broad knowledge of the pharmaceutical industry and of the finance community that supports life sciences. He sits as an independent member on the boards of several biotech companies and advises Investment partnerships.
He was co-founder and Chief Scientific Officer of Kymab Limited, a biopharmaceutical company later acquired by Sanofi. Before that he held several senior Leadership positions at GlaxoSmithKline.
His experience therefore spans large pharmaceutical research, the founding and sale of a venture-backed biotech, and board roles at both listed and private life sciences companies. That background is relevant to a diagnostics Business such as EDX, which works alongside industry partners and relies on access to capital markets. The company did not say whether he will take on any committee roles.
Disclosures under the AIM Rules
As required under Schedule Two, paragraph (g) of the AIM Rules for Companies, EDX disclosed Professor Owen's directorships over the past five years.
His current directorships are Ossianix Inc, where he is Chairman; Sareum Holdings plc, where he chairs the Remuneration Committee and sits on the Audit Committee; NovalGen Ltd; Istesso Ltd; and Club Cricket Organisation Limited.
His past directorships within the period are Zealand Pharma A/S, ReNeuron Group Limited, Gamma Delta Therapeutics Limited and Iksuda Therapeutics Limited.
The company disclosed that ReNeuron Group Limited entered administration on 20 March 2024 and exited it on 17 March 2025. EDX states that the purpose of the administration was achieved and that creditor claims were settled in full. Professor Owen was a director of ReNeuron from December 2015 to March 2025.
Professor Owen holds no ordinary shares in EDX. The announcement does not mention any share options. The company said there is no further information to disclose under Schedule Two, paragraph (g).
What the company said
Professor Owen said: "I am delighted to be joining and chairing the board of EDX Medical."
Founder Sir Chris Evans said: "We are thrilled to welcome Mike Owen to EDX Medical."
Outgoing chair Jason Holt said: "We have made an excellent choice of new chairman."
Background on EDX Medical
EDX Medical develops digital diagnostic products and services. It operates facilities in Cambridge, UK, and its partnerships include one with Thermo Fisher EMEA Ltd. The announcement does not include any trading or financial update.
Canaccord Genuity acts as the company's nominated adviser and broker.
What to watch next
As this is a board change, attention may turn to how the new chair shapes the company's strategy and its links with the life sciences investment community, given Professor Owen's background in pharmaceutical R&D and biotech investment. Investors may also watch for any future dealings in EDX shares by Professor Owen, who holds none at present, and for the company's next trading or commercial update.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...